1189678-81-6
1189678-81-6
Chemical Structure
Salicylic acid-13C6
Synonym(s): 2-Hydroxybenzoic acid-13C6
- CAS No.: 1189678-81-6
- Formula:C13C6H6O3
- Molecular Weight:144.08
IUPAC Name: 2-hydroxybenzoic-1,2,3,4,5,6-13C6 acid
InChIKey: YGSDEFSMJLZEOE-IDEBNGHGSA-N
SMILES: OC([13C]1=[13C]([13CH]=[13CH][13CH]=[13CH]1)O)=O
Biological Activity: Salicylic acid-13C6 is the 13C-labeled Salicylic acid (HY-B0167). Salicylic acid is a precursor to and a metabolite of Aspirin (HY-14654), can inhibit cyclo-oxygenase-2 (COX-2) activity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Salicylic acid-13C6 | 97.0% | Salicylic acid-13C6 is the 13C-labeled Salicylic acid (HY-B0167). Salicylic acid is a precursor to and a metabolite of Aspirin (HY-14654), can inhibit cyclo-oxygenase-2 (COX-2) activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salicylic acid (Standard) | 98.00% | Salicylic acid (Standard) is the analytical standard of Salicylic acid. This product is intended for research and analytical applications. Salicylic acid (2-Hydroxybenzoic acid) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-Carboxyphenol-d4 | 99.83% | 2-Carboxyphenol-d4 is the deuterium labeled 2-Carboxyphenol. 2-Carboxyphenol is a plant hormone and mediates host responses against microbial pathogens. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salicylic acid-d6 | 99.82% | Salicylic acid-d6 is a deuterium labeled Salicylic acid (HY-B0167). Salicylic acid inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salicylic acid | 98.12% | Salicylic acid (2-Hydroxybenzoic acid) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation. Salicylic acid has blood-brain barrier permeability. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Mitchell JA, et al. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol. 1997 Jun;51(6):907-12.;Nixon M, et al. Salicylate downregulates 11 [Content Brief]
